+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID07570745

Preventing Acute Graft-versus-Host Disease with Low-Dose ATG, Post-Transplant Cyclophosphamide, and Ivarmacitinib in Adults Receiving Haploidentical Peripheral Blood Stem Cell Transplants from Parous Female Donors

Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-05-06

82

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Graft-versus-host disease GVHD is a serious complication after allogeneic hematopoietic stem cell transplantation, affecting survival and quality of life. Acute GVHD usually occurs within 100 days post-transplant, involving the skin, gastrointestinal tract, and liver, while chronic GVHD can develop months to years later. Despite current treatments like calcineurin inhibitors and post-transplant cyclophosphamide, recipients of haploidentical transplants from parous female donors remain at high risk for moderate-to-severe acute GVHD. This trial studies the effect of adding a selective JAK1 inhibitor, Ivarmacitinib, to standard low-dose ATG and cyclophosphamide to reduce GVHD in this high-risk group. Participants will receive rabbit anti-thymocyte globulin ATG at 2.5 mgkg on days -2 and -1 before transplant, cyclophosphamide 50 mgkg on day 3, and begin cyclosporine and mycophenolate mofetil on day 4. Ivarmacitinib, an oral JAK1 inhibitor, will be given at 4 mg daily from day -3 to 45, then reduced to 2 mg daily from day 46 to 60. This combination aims to prevent acute GVHD while preserving necessary immune functions. The study is a prospective, single-arm, multicenter trial focused on haploidentical peripheral blood stem cell transplantation from parous female donors. During the study, participants will be monitored for acute GVHD incidence up to 180 days post-transplant, graft failure by day 28, and non-relapse mortality by day 180. Assessments include regular clinical evaluations, laboratory tests, and safety monitoring. Participants are expected to comply with follow-up visits and related examinations throughout the study duration. The trial seeks to improve GVHD prevention and overall transplant outcomes in this high-risk population.

CONDITIONS

Brief Title

Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

Research Team

X

Xianmin Song, PhD

X

Xianmin Song, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here